Vnitr Lek 2017, 63(5):333-337 | DOI: 10.36290/vnl.2017.067

News in the treatment of hypertension and dyslipidemia

Jan Václavík
I. interní klinika - kardiologická LF UP v Olomouci a FN Olomouc

These review article presents the results of major recent studies in cardiovascular prevention. HOPE-3 study showed that people with medium cardiovascular risk who have not experienced a cardiovascular event, and have normal blood pressure, benefit from deploying a statin, and in the presence of hypertension benefit from deploying a combination of a statin and antihypertensive drugs. Studies evaluating genetic predisposition brought new evidence that both LDL cholesterol and systolic blood pressure are independent and multiplicative causal risk factors for cardiovascular events. A mild long-term reduction in blood pressure and LDL cholesterol has the potential to significantly reduce the lifetime risk of cardiovascular events. In the final section the article discusses options for improving patient adherence to antihypertensive and lipid treatment and the new available fixed combinations for these diseases.

Keywords: arterial hypertension; cardiovascular prevention; dyslipidemia; fixed combinations; treatment

Received: April 12, 2017; Accepted: May 28, 2017; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Václavík J. News in the treatment of hypertension and dyslipidemia. Vnitr Lek. 2017;63(5):333-337. doi: 10.36290/vnl.2017.067.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yusuf S, Lonn E, Pais P et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2032-2043. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600177>. Go to original source... Go to PubMed...
    2. Widimský J. Komentář ke článku HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients. Vnitř Lék 2016; 62(6): 474-476. Go to PubMed...
    3. Yusuf S, Bosch J, Dagenais G et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2021-2031. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600176>. Go to original source... Go to PubMed...
    4. Lonn EM, Bosch J, López-Jaramillo P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2009-2020. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600175>. Go to original source... Go to PubMed...
    5. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc>. Go to original source... Go to PubMed...
    6. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>. Go to original source... Go to PubMed...
    7. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25(6): 484-491. Go to original source... Go to PubMed...
    8. Ference B, Ference T, Brook RD et al. A naturally randomized trial comparing the effect of long-term exposure to lower LDL-C, lower SBP, or both on the risk of cardiovascular disease. ESC Congr 2016. Rome: 2016. p. FP Number: 3163.
    9. Jin J, Sklar GE, Min Sen Oh V et al. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008; 4(1): 269-286. Go to original source...
    10. Fung V, Huang J, Brand R et al. Hypertension treatment in a medicare population: Adherence and systolic blood pressure control. Clin Ther 2007; 29(5): 972-984. Go to original source... Go to PubMed...
    11. Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24(2): 302-316. Go to original source... Go to PubMed...
    12. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147-1152. Go to original source... Go to PubMed...
    13. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713-719. Go to original source... Go to PubMed...
    14. Egan BM, Bandyopadhyay D, Shaftman SR et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59(6): 1124-1131. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.194167>. Go to original source... Go to PubMed...
    15. Státní ústav pro kontrolu léčiv. Lipertance. Souhrn údajů o přípravku. [Internet]. 2016. Report No.: sukls288225/2016. Dostupné z WWW: <http://www.sukl.cz/modules/medication/download.php?file=SPC106789.pdf&type=spc&as=lipertance-spc>.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.